Floatz logo

Piritramide

Colon Cancer

The Institute of Molecular and Translational Medicine, Czech RepublicSmall moleculePhase 4 / ApprovedDormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
65/ 100

Competitive context

158 Active assets in the Colon Cancer cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Akeso
Phase 4A
Irinotecan
Fudan University
Phase 3BBB
Floxuridine
City of Hope Medical Center
Phase 2BBB
FLUOROURACILUM
Akeso
Phase 4BB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

Piritramide is also rated in:

Circulating Tumor CellDormant
BB
Indicative ·
71 / 100
View asset →
Minimal Residual DiseaseDormant
B
Indicative ·
62 / 100
View asset →
colorectal cancerDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →